Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed
qz.com › amgen-maritide-weight-loss-20-1851708482
This story seems to be about:
This story seems to be about:
Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and potential Ozempic competitor MariTide, however, Wall Street wasn’t very impressed.